Literature DB >> 18562217

Epileptic seizures as the sole manifestation of neuro-Behçet's disease: complete control under interferon-alpha treatment.

Elisabeth Chroni1, Alexandra Monastirli, Panayiotis Polychronopoulos, Efi Pasmatzi, Sophia Georgiou, Eleftheria Vryzaki, Dionysios Tsambaos.   

Abstract

Behçet's disease (BD) is a multisystemic disease of unknown etiopathogenesis with various clinical features including manifestations from central nervous system involvement. We report the case of a patient presented with a 20-year history of BD and a 10-year history of epileptic seizures refractory to various antiepileptic drugs. Under systemic treatment with interferon-alpha 2a (IFN-alpha) a complete remission of the cutaneous manifestations and a seizure-free state were achieved. The impressive therapeutic response of both the seizures and the non-neurological manifestations to IFN-alpha was also observed upon re-administration of this cytokine subsequent to a severe BD relapse. In view of this response and the lack of any other obvious etiology of the seizures in our patient, it seems reasonable to consider them as being the sole manifestation of neuro-BD. The patient is presently completing a 40-month seizure-free follow-up, despite withdrawal of all antiepileptic drugs for the last 35 months. Further studies on large numbers of patients are now warranted to define the therapeutic efficacy and safety of IFN-alpha in neuro-BD and particularly in neuro-BD-related epileptic seizures.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18562217     DOI: 10.1016/j.seizure.2008.05.008

Source DB:  PubMed          Journal:  Seizure        ISSN: 1059-1311            Impact factor:   3.184


  4 in total

Review 1.  Update on the therapy of Behçet disease.

Authors:  Zeinab Saleh; Thurayya Arayssi
Journal:  Ther Adv Chronic Dis       Date:  2014-05       Impact factor: 5.091

2.  Systemic lupus erythematosus manifested as drug-resistant mesial temporal lobe epilepsy.

Authors:  P Polychronopoulos; G Giannopoulos; P Litsardopoulos; P Soldatos; E Chroni
Journal:  Neurol Sci       Date:  2016-09-03       Impact factor: 3.307

3.  [Progress in interferon: A treatment of Behcet syndrome].

Authors:  D Yan; W J Zheng
Journal:  Beijing Da Xue Xue Bao Yi Xue Ban       Date:  2020-12-18

4.  Effectiveness and safety of low-dose interferon alpha-2a treatment in Behçet's Syndrome with refractory vascular or neurological involvement: a case series.

Authors:  Luxi Sun; Yunxia Hou; Lifan Zhang; JinJing Liu; Lu Li; Zhimian Wang; Xin Yu; Menghao Zhang; Xiaoqing Liu; Yan Zhao; Wenjie Zheng
Journal:  Ther Adv Chronic Dis       Date:  2022-07-26       Impact factor: 4.970

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.